Targeting PCK1 to overcome CDK4/6 inhibitor resistance for breast cancer therapy.

Saved in:
Bibliographic Details
Title: Targeting PCK1 to overcome CDK4/6 inhibitor resistance for breast cancer therapy.
Authors: Wu CS; Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan; Cancer Biology and Precision Therapeutics Center and Research Center for Cancer Biology, China Medical University, Taichung, Taiwan; Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan., Chen HF; Graduate Institutes of Cell Biology, China Medical University, Taichung, Taiwan., Huynh KT; Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan; Center for Molecular Medicine, China Medical University Hospital, China Medical University, Taichung, Taiwan., Huang WC; Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan; Cancer Biology and Precision Therapeutics Center and Research Center for Cancer Biology, China Medical University, Taichung, Taiwan; Center for Molecular Medicine, China Medical University Hospital, China Medical University, Taichung, Taiwan., Li YC; Cancer Biology and Precision Therapeutics Center and Research Center for Cancer Biology, China Medical University, Taichung, Taiwan; Department of Biological Science and Technology, China Medical University, Taichung, Taiwan., Chang WC; Cancer Biology and Precision Therapeutics Center and Research Center for Cancer Biology, China Medical University, Taichung, Taiwan; Center for Molecular Medicine, China Medical University Hospital, China Medical University, Taichung, Taiwan., Chang LC; Cancer Biology and Precision Therapeutics Center and Research Center for Cancer Biology, China Medical University, Taichung, Taiwan; Center for Molecular Medicine, China Medical University Hospital, China Medical University, Taichung, Taiwan., Jiang CL; Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan; Cancer Biology and Precision Therapeutics Center and Research Center for Cancer Biology, China Medical University, Taichung, Taiwan., Huang KC; Department of Biomedical Imaging and Radiological Science, China Medical University, Taichung, Taiwan; Translation Research Core, China Medical University Hospital, China Medical University, Taichung, Taiwan., Liu LC; Department of Breast Surgery, China Medical University Hospital, Taichung, Taiwan., Chao KSC; Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan; Proton Therapy and Science Center, China Medical University Hospital, China Medical University, Taichung, Taiwan; Department of Radiation Oncology, China Medical University Hospital, China Medical University, Taichung, Taiwan., Hung MC; Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan; Cancer Biology and Precision Therapeutics Center and Research Center for Cancer Biology, China Medical University, Taichung, Taiwan; Center for Molecular Medicine, China Medical University Hospital, China Medical University, Taichung, Taiwan; Institute of Biochemistry and Molecular Biology, China Medical University, Taichung, Taiwan; Department of Biotechnology, Asia University, Taichung, Taiwan. Electronic address: mhung@cmu.edu.tw.
Source: Cancer letters [Cancer Lett] 2026 May 01; Vol. 645, pp. 218349. Date of Electronic Publication: 2026 Feb 24.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Science Ireland Country of Publication: Ireland NLM ID: 7600053 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-7980 (Electronic) Linking ISSN: 03043835 NLM ISO Abbreviation: Cancer Lett Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1872-7980
DOI:10.1016/j.canlet.2026.218349